Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Pharma
FDA approves Takeda's first-in-class Orzeyful for narcolepsy
Takeda has scored an FDA approval for potential blockbuster Orzeyful, a first-in-class drug for adults with narcolepsy type 1.
Kevin Dunleavy
Aug 6, 2026 11:10am
Fierce Biotech
Biopharma R&D pipeline shrinks for 1st time in 30 years: report
Apr 3, 2026 8:13am
Servier revenue growth hits 16% as group eyes €10B 2030 goal
Jan 27, 2026 10:55am
After Avadel setback, Lundbeck signals future M&A rigor
Jan 22, 2026 11:13am
Neurocrine's Ingrezza misses in cerebral palsy trial
Dec 23, 2025 10:20am
What's on neurologists' minds? Not drug names, survey shows
Jul 18, 2025 10:10am
